Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study

This publication has 22 references indexed in Scilit:

• Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
  Journal of Clinical Oncology, 2011
• Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival
  Annals of Surgery, 2010
• DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
  Journal of Clinical Oncology, 2009
• Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
  Journal of Clinical Oncology, 2008
• Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
  Pancreas, 2008
• Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
  Cancer, 2006
• Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma
  Journal of Clinical Oncology, 2006
• Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 2002
• Tumor markers in patients with pancreatic carcinoma
  Cancer, 1996
• Prognostic Value of Serum CA 19–9 Levels in Pancreatic Adenocarcinoma
  Annals of Surgery, 1992